vTv Therapeutics announces participation in upcoming investor conferences to discuss cadisegliatin, a potential type 1 diabetes treatment.
Quiver AI Summary
vTv Therapeutics Inc., a late-stage biopharmaceutical company focused on developing cadisegliatin, an innovative oral adjunctive therapy for type 1 diabetes, announced its management's participation in upcoming investor conferences: the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, and the TD Cowen 46th Annual Health Care Conference on March 3, 2026. Cadisegliatin, currently in a Phase 3 trial in the U.S. and granted Breakthrough Therapy designation by the FDA, is a liver-selective glucokinase activator aimed at improving glycemic control in T1D. The company continues to explore various therapeutic molecules for chronic diseases and encourages interest in their developments through their website and social media platforms.
Potential Positives
- vTv Therapeutics is preparing to present at significant investor conferences, showcasing confidence in their pipeline and ability to attract investment.
- Cadisegliatin has received Breakthrough Therapy designation from the FDA, indicating its potential and the regulatory body's recognition of its importance in treating type 1 diabetes.
- The company is in a US Phase 3 trial for cadisegliatin, which is a crucial step in bringing a new treatment option to market for type 1 diabetes.
Potential Negatives
- The press release states that cadisegliatin's safety and efficacy have not been established, which may raise concerns among investors and stakeholders about the viability and future of the product.
- Despite being under investigation, there is no guarantee that cadisegliatin will receive regulatory approval or become commercially available, which could negatively impact the company's future revenue potential.
FAQ
What is vTv Therapeutics focusing on?
vTv Therapeutics is focused on developing cadisegliatin, a potential first-in-class oral therapy for type 1 diabetes.
What upcoming investor conferences will vTv attend?
vTv will attend the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the TD Cowen 46th Annual Health Care Conference.
When is the Oppenheimer Healthcare Conference?
The Oppenheimer 36th Annual Healthcare Life Sciences Conference is on February 26, 2026, at 11:20 AM ET.
What is cadisegliatin?
Cadisegliatin is an oral glucokinase activator being investigated as a treatment for type 1 diabetes in a Phase 3 trial.
Has cadisegliatin received any special designations?
Yes, cadisegliatin has been granted Breakthrough Therapy designation by the U.S. FDA.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$VTVT Revenue
$VTVT had revenues of $17K in Q4 2024.
You can track VTVT financials on Quiver Quantitative's VTVT stock page.
$VTVT Hedge Fund Activity
We have seen 13 institutional investors add shares of $VTVT stock to their portfolio, and 5 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SAMSARA BIOCAPITAL, LLC added 167,677 shares (+81.1%) to their portfolio in Q3 2025, for an estimated $3,915,257
- SIREN, L.L.C. added 163,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $3,806,050
- BAKER BROS. ADVISORS LP added 51,000 shares (+52.4%) to their portfolio in Q3 2025, for an estimated $1,190,850
- VANGUARD GROUP INC added 36,410 shares (+77.5%) to their portfolio in Q4 2025, for an estimated $1,456,035
- FMR LLC added 14,691 shares (+8.2%) to their portfolio in Q3 2025, for an estimated $343,034
- GEODE CAPITAL MANAGEMENT, LLC added 12,896 shares (+84.3%) to their portfolio in Q4 2025, for an estimated $515,711
- PATHSTONE HOLDINGS, LLC added 6,073 shares (+inf%) to their portfolio in Q4 2025, for an estimated $242,859
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$VTVT Analyst Ratings
Wall Street analysts have issued reports on $VTVT in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 12/19/2025
- BTIG issued a "Buy" rating on 11/19/2025
To track analyst ratings and price targets for $VTVT, check out Quiver Quantitative's $VTVT forecast page.
$VTVT Price Targets
Multiple analysts have issued price targets for $VTVT recently. We have seen 4 analysts offer price targets for $VTVT in the last 6 months, with a median target of $53.5.
Here are some recent targets:
- Kambiz Yazdi from BTIG set a target price of $49.0 on 01/27/2026
- Adam Walsh from Roth Capital set a target price of $58.0 on 01/23/2026
- Ritu Baral from TD Cowen set a target price of $67.0 on 01/05/2026
- Emily Bodnar from HC Wainwright & Co. set a target price of $47.0 on 12/19/2025
Full Release
HIGH POINT, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin , a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following upcoming investor conferences:
Oppenheimer 36th Annual Healthcare Life Sciences Conference
Date: Thursday, February 26, 2026
Time: 11:20 AM ET
Format: Presentation Only
Location: Virtual
Webcast Link
TD Cowen 46th Annual Health Care Conference
Date: Tuesday, March 3, 2026
Time: 9:50 AM ET
Format: Presentation and 1x1 Meetings
Location: Boston, MA
Webcast Link
About
vTv
Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by
cadisegliatin
, currently in a US Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at
vtvtherapeutics.com
or follow the company on
LinkedIn
or
X
.
About Cadisegliatin
Cadisegliatin (TTP399)
is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the US as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies,
cadisegliatin
, acting selectively on the liver, increased the activity of glucokinase independently from insulin which supports clinical investigation of improvement in glycemic control through hepatic glucose uptake and glycogen storage.
Cadisegliatin
has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).
Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.
Investor Contact
John Fraunces
LifeSci Advisors, LLC
[email protected]
Media Contact
Caren Begun
TellMed Strategies
201-396-8551
[email protected]
